Monday, September 16, 2013
For the first time, DRI
Capital plans to seek potential royalties from Phase III compounds rather
than from marketed drugs. To do so the firm will use up to 25% of proceeds from
its newly closed $1.5 billion Drug Royalty III, which DRI said is the largest
ever private equity fund focused on healthcare royalties.
The fundraising took about 12
months and was oversubscribed, with an original target of